SupplySide West session focuses on power of AISupplySide West session focuses on power of AI
AI is a tool that many dietary supplement companies already use. This session coveres key issues in the category, including how companies can benefit from this technology and what are the major sticking points. Price: $50
Already purchased?
At a Glance
- AI tools are already used by many supplement companies.
- Some developments in the industry would have been impossible without these tools.
- Panel discussion covers the big things companies need to know before taking that plunge.
The world of dietary supplements is rapidly evolving. This session explores how artificial intelligence (AI) and other cutting-edge technologies are changing the game in supplement formulation The panelists explained how AI has helped them to analyze vast datasets to identify novel ingredient combinations and predict potential health benefits. Essentially it has allowed some of these companies to do things that would have unfeasible by other means.
The panelists for this session are Weslee Glenn, vice president of innovation at Ayana Bio, Mike Bush managing partner at GrowthWays Partners, Camille Delebecque, head of biotechnology at VerbBiotics and Scott Forsberg, president of Vine to Bar.
Timeline:
0:00 to 5:11 Introduction and questions posed to audience.
5:11 to 11:30 Panelists describe how they use AI in their ingredient development efforts and consulting practices.
11:30 to 14:45 Discussion of how consumers view products developed using AI. Are they intrigued, or do they feel threatened?
14:45 to 19:45 Is AI helping to bolster the scientific backing of dietary supplements and their claims, or is it making things worse with a proliferation of questionable research papers?
19:45 to 24:03 Delebecque describes how AI enabled VerbBiotics to discover novel probiotic organisms in a way that would not have been possible otherwise. Glenn chimes in with how AI helped Ayana Bio streamline their production processes.
24:03 to 27:30. Does AI help find novel solutions that can bolster a company’s IP?
27:30 to 29:25. Is AI all about finding new ingredients that could ultimately be marketed as drugs?
29:25 to 31:50. Is AI raising the regulatory risk concerning de novo ingredients?
31:50 to 35:00. Is using AI on a reductionist development path really the best use of the technology for the natural products industry?
35:00 to 36:00. Is AI useful for understanding the so-called “entourage effect?”
36:00 to 38:20. What about the “hallucinations” that have been observed in AI outputs?
38:20 to 41:30. Can AI help de-risk the scale-up process for new ingredients?
41:30 to 59.30. Questions from audience.
Price: $50
Read more about:
Premium contentAbout the Author
You May Also Like